These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1537053)

  • 1. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).
    Kleinerman ES; Raymond AK; Bucana CD; Jaffe N; Harris MB; Krakoff IH; Benjamin R; Fidler IJ
    Cancer Immunol Immunother; 1992; 34(4):211-20. PubMed ID: 1537053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
    Mori K; Ando K; Heymann D
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs.
    Bezault J; Walsh C; Tarcsay L; Frost H; Liebes L; Furmanski P
    In Vivo; 1993; 7(6A):487-91. PubMed ID: 8193265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
    Fujimaki W; Itoh K; An T; Gano JB; Ross MI; Mansfield PF; Balch CM; Augustus LB; Karkevitch DD; Johnston D
    Cancer Biother; 1993; 8(4):307-18. PubMed ID: 7804372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
    Kleinerman ES; Snyder JS; Jaffe N
    J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.
    MacEwen EG; Kurzman ID; Helfand S; Vail D; London C; Kisseberth W; Rosenthal RC; Fox LE; Keller ET; Obradovich J
    J Drug Target; 1994; 2(5):391-6. PubMed ID: 7704483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.
    Drugs R D; 2008; 9(2):131-5. PubMed ID: 18298131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Fujimaki W; Griffin JR; Kleinerman ES
    Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
    Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
    Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
    MacEwen EG; Kurzman ID; Rosenthal RC; Smith BW; Manley PA; Roush JK; Howard PE
    J Natl Cancer Inst; 1989 Jun; 81(12):935-8. PubMed ID: 2733037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
    Anderson P
    Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
    Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
    Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
    Kleinerman ES; Jaffe N
    Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583
    [No Abstract]   [Full Text] [Related]  

  • 20. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
    Gianan MA; Kleinerman ES
    Cancer Biother Radiopharm; 1998 Oct; 13(5):363-8. PubMed ID: 10851426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.